SLC5A3 and diffuse large B-cell lymphoma: Further experiments were performed to uncover the underlying mechanism of SMIT1 in DLBCL progression using the AKT agonist SC-79, which allows AKT to be phosphorylated by upstream kinases in the cytoplasm.